Table 1.
Participants’ demographic and medication data
| Oral drug (n=241) |
LAI (n=29) |
P-value | |
|---|---|---|---|
| Age (years) | 51.68±15.65 | 46.90±11.94 | 0.056 |
| Sex (male/female) | 99/142 | 8/21 | 0.160 |
| Inpatient/outpatient | 57/184 | 5/24 | 0.438 |
| Duration of illness (years) | 20.13±14.71 | 14.71±11.40 | 0.143 |
| Smoking (smoker/non-smoker) | 20/221 | 1/28 | 0.357 |
| BMI (kg/m2) | 24.15±4.46 | 24.16±5.25 | 0.989 |
| CPZeqb (mg/day) | 459.23±232.88 | 564.0345±197.63 | 0.021a |
| BPDeqc (mg/day) | 0.82±1.54 | 1.21±2.11 | 0.227 |
| DZPeqd (mg/day) | 5.92±8.76 | 8.15±11.62 | 0.214 |
| PANSS total score | 71.69±15.25 | 72.69±16.89 | 0.743 |
Notes: Data are presented as mean±SD. Age, duration of illness, BMI, CPZeq, BPDeq, DZPeq, and PANSS total score were compared between the groups using t-tests. The proportions of men/women, inpatients/outpatients, and smokers/nonsmokers were compared between the groups using a chi-squared test.
Significant difference (P<0.05; t-test).
Daily dose of antipsychotic drugs was converted to an approximate chlorpromazine equivalent.
Daily dose of anticholinergic antiparkinsonian drugs was converted to an approximate biperiden equivalent.
Daily dose of benzodiazepine was converted to an approximate diazepam equivalent.
Abbreviations: BMI, body mass index; BPDeq, biperiden equivalent; CPZeq, chlorpromazine equivalent; DZPeq, diazepam equivalent; LAI, long-acting injection; PANSS, Positive and Negative Syndrome Scale.